Evidence map›Paper›PMID 42037460›Full record

ArticleClinical and translational science2026

Advancing Pharmacoequity in Low- and Middle-Income Countries via Model Informed Drug Development.

Henry Enzama, Francis Williams Ojara, Ian S Haworth, Sandra Cvijic, Catriona Waitt, Thaddeus H Grasela

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Henry EnzamaInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID 0009-0000-1901-9404
Francis Williams OjaraInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.ORCID 0000-0002-6425-6828
Ian S HaworthDepartment of Pharmacology and Pharmaceutical Sciences, USC Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-3873-0899
Sandra CvijicDepartment of Pharmaceutical Technology and Cosmetology, University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia.ORCID 0000-0001-8291-791X
Catriona WaittDepartment of Women's and Children's Health, University of Liverpool, Liverpool, UK.ORCID 0000-0003-0134-5855
Thaddeus H GraselaAzimuth Global Health Consulting, Buffalo, New York, USA.ORCID 0000-0002-2103-8206

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Across low- and middle-income countries (LMICs) inequities in access to safe, effective medicines persist due to limited regulatory capacity, inadequate financing, and insufficient local data. Regulatory authorities are engaging with model-informed drug development (MIDD), but uneven technical readiness and resource gaps limit uptake. Physiologically based and population pharmacokinetic modeling can strengthen regulatory review and optimize dosing. When aligned with global harmonization initiatives, these tools can support evidence-based decisions and advance pharmacoequity by ensuring context-appropriate therapies reach patients.

Indexed as

Developing CountriesDrug DevelopmentEconomics, PharmaceuticalHumans

Identifiers

PMID42037460
PMCPMC13112073

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.